Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...
Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) and Captain T Cell, a spinoff from the renowned Max Delbrück Center Berlin, Germany, today announced a ...
Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...
Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...
Autonomous parvoviruses possess an intrinsic oncotropism based on viral genetic elements controlling gene expression and genome replication. We constructed a hybrid vector consisting of the H1 ...
No vector-related safety concerns have been noted in any patient in the study who received gene-modified hematopoietic stem cells; specifically, no leukoproliferative or myelodysplastic complications, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback